Progress in the development of recombinant and synthetic blood-stage malaria vaccines

Journal of Experimental Biology

Volumn 206, Issue 21, 2003, Pages 3781-3788

  Mahanty, Siddhartha ^a   Saul, Allan ^a   Miller, Louis H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antigenic polymorphism; Blood stage; Clinical trials; Malaria; Plasmodium falciparum; Recombinant antigen; Vaccine

Indexed keywords

MALARIA VACCINE; PARASITE ANTIGEN; RECOMBINANT VACCINE;

ANIMAL; CLINICAL TRIAL; IMMUNOLOGY; LIFE CYCLE; MALARIA FALCIPARUM; PATHOGENICITY; PLASMODIUM FALCIPARUM; REVIEW;

ANIMALS; ANTIGENS, PROTOZOAN; CLINICAL TRIALS; LIFE CYCLE STAGES; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; VACCINES, SYNTHETIC;

ANIMALIA; PLASMODIUM FALCIPARUM;

EID: 0242490284     PISSN: 00220949     EISSN: None     Source Type: Journal    
DOI: 10.1242/jeb.00646     Document Type: Review

References (84)

1. Aikawa, M., Miller, L. H., Johnson, J. and Rabbege, J. (1978). Erythrocyte entry by malarial parasites. A moving junction between erythrocyte and parasite. J. Cell Biol. 77, 72-82.
2. Amante, F. H. and Good, M. F. (1997). Prolonged Th1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice. Parasite Immunol. 19, 111-126.
3. Anders, R. F. and Saul, A. (2000). Malaria vaccines. Parasitol. Today 16, 444-447.
4. Andre, F. E. (2003). Vaccinology: past achievements, present roadblocks and future promises. Vaccine 21, 593-595.
5. Aoki, S., Li, J., Itagaki, S., Okech, B. A., Egwang, T. G., Matsuoka, H., Palacpac, N. M., Mitamura, T. and Horii, T. (2002). Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth. J. Biol. Chem. 277, 47533-47540.
6. Badell, E., Oeuvray, C., Moreno, A., Soe, S., van Rooijen, N., Bouzidi, A. and Druilhe, P. (2000). Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum. J. Exp. Med. 192, 1653-1660.
7. Baruch, D. I., Gamain, B., Barnwell, J. W., Sullivan, J. S., Stowers, A., Galland, G. G., Miller, L. H. and Collins, W. E. (2002). Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line. Proc. Natl. Acad. Sci. USA 99, 3860-3865.
8. Baruch, D. I., Gormely, J. A., Ma, C., Howard, R. J. and Pasloske, B. L. (1996). Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. Proc. Natl. Acad. Sci. USA 93, 3497-3502.
9. Baruch, D. I., Ma, X. C., Singh, H. B., Bi, X., Pasloske, B. L. and Howard, R. J. (1997). Identification of a region of PfEMP1 that mediates adherence of Plasmodium falciparum infected erythrocytes to CD36: conserved function with variant sequence. Blood 90, 3766-3775.
10. Berzins, K., Perlmann, H., Wahlin, B., Ekre, H. P., Hogh, B., Petersen, E., Wellde, B., Schoenbechler, M., Williams, J. and Chulay, J. (1991). Passive immunization of Aotus monkeys with human antibodies to the Plasmodium falciparum antigen Pf155/RESA. Infect. Immunol. 59, 1500-1506.
11. Bojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R., Conway, D. J., Reece, W. H., Gothard, P. et al. (2001). Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358, 1927-1934.
12. Bonanni, P. (1999). Demographic impact of vaccination: a review. Vaccine 17 Suppl. 3, S120-S125.
13. Bouharoun-Tayoun, H., Attanath, P., Sabchareon, A., Chongsuphajaisiddhi, T. and Druilhe, P. (1990). Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 172, 1633-1641.
14. Bouharoun-Tayoun, H., Oeuvray, C., Lunel, F. and Druilhe, P. (1995). Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 182, 409-418.
15. Brake, D. A., Long, C. A. and Weidanz, W. P. (1988). Adoptive protection against Plasmodium chabaudi adami malaria in athymic nude mice by a cloned T cell line. J. Immunol. 140, 1989-1993.
16. Bull, P. C., Lowe, B. S., Kortok, M., Molyneux, C. S., Newbold, C. I. and Marsh, K. (1998). Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat. Med. 4, 358-360.
17. Bull, P. C. and Marsh, K. (2002). The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol. 10, 55-58.
18. Cohen, S., McGregor, I. A. and Carrington, S. ( 1961). Gamma globulin and acquired immunity to human malaria. Nature 192, 733-737.
19. Collins, W. E., Anders, R. F., Pappaioanou, M., Campbell, G. H., Brown, G. V., Kemp, D. J., Coppel, R. L., Skinner, J. C., Andrysiak, P. M. and Favaloro, J. M. (1986). Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature 323, 259-262.
20. Collins, W. E., Walduck, A., Sullivan, J. S., Andrews, K., Stowers, A., Morris, C. L., Jennings, V., Yang, C., Kendall, J., Lin, Q. et al. (2000). Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri boliviensis monkeys. Am. J. Trop. Med. Hyg. 62, 466-479.
21. Cowman, A. F., Baldi, D. L., Duraisingh, M., Healer, J., Mills, K. E., O'Donnell, R. A., Thompson, J., Triglia, T., Wickham, M. E. and Crabb, B. S. (2002). Functional analysis of Plasmodium falciparum merozoite antigens: implications for erythrocyte invasion and vaccine development. Phil. Trans. R. Soc. Lond. B 357, 25-33.
22. Cox, J. C. and Coulter, A. R. (1997). Adjuvants - a classification and review of their modes of action. Vaccine 15, 248-256.
23. Daly, T. M. and Long, C. A. (1996). Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Infect. Immunol. 64, 2602-2608.
24. Deans, J. A. (1984). Protective antigens of bloodstage Plasmodium knowlesi parasites. Phil. Trans. R. Soc. Lond. B 307, 159-169.
25. Druilhe, P. and Bouharoun-Tayoun, H. (2002). Antibody-dependent cellular inhibition assay. Meth. Mol. Med. 72, 529-534.
26. Dvorak, J. A., Miller, L. H., Whitehouse, W. C. and Shiroishi, T. (1975). Invasion of erythrocytes by malaria merozoites. Science 187, 748-750.
27. Egan, J. E., Hoffman, S. L., Haynes, J. D., Sadoff, J. C., Schneider, I., Grau, G. E., Hollingdale, M. R., Ballou, W. R. and Gordon, D. M. ( 1993). Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 49, 166-173.
28. Genton, B., Al-Yaman, F., Anders, R., Saul, A., Brown, G., Pye, D., Irving, D. O., Briggs, W. R., Mai, A., Ginny, M. et al. (2000). Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 18, 2504-2511.
29. Genton, B., Betuela, I., Felger, I., Al-Yaman, F., Anders, R. F., Saul, A., Rare, L., Baisor, M., Lorry, K., Brown, G. V. et al. (2002). A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185, 820-827.
30. Genton, B. and Corradin, G. (2002). Malaria vaccines: from the laboratory to the field. Curr. Drug Targets Immune Endocrinol. Metabol. Disord. 2, 255-267.
31. Good, M. F. (2001). Towards a blood-stage vaccine for malaria: are we following all the leads? Nat. Rev. Immunol. 1, 117-125.
32. Good, M. F. and Doolan, D. L. (1999). Immune effector mechanisms in malaria. Curr. Opin. Immunol. 11, 412-419.
33. Good, M. F., Kaslow, D. C. and Miller, L. H. (1998). Pathways and strategies for developing a malaria blood-stage vaccine. Annu. Rev. Immunol. 16, 57-87.
34. Gordon, D. M. (1993). Use of novel adjuvants and delivery systems to improve the humoral and cellular immune response to malaria vaccine candidate antigens. Vaccine 11, 591-593.
35. Gordon, D. M., McGovern, T. W., Krzych, U., Cohen, J. C., Schneider, I., LaChance, R., Heppner, D. G., Yuan, G., Hollingdale, M., Slaoui, M. et al. (1995). Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171, 1576-1785.
36. Graves, P. and Gelbrand, H. (2003). Vaccines for preventing malaria (Cochrane Review). In Cochrane Database Syst. Rev., vol. 2, pp. 1-35. Oxford: Update Software.
37. Greenwood, B. and Alonso, P. (2002). Malaria vaccine trials. Chem. Immunol. 80, 366-395.
38. Heppner, D. G., Cummings, J. F., Ockenhouse, C., Kester, K. E., Lyon, J. A. and Gordon, D. M. (2001). New World monkey efficacy trials for malaria vaccine development: critical path or detour? Trends Parasitol. 17, 419-425.
39. Hill, A. V. (1999). The immunogenetics of resistance to malaria. Proc. Assn. Am. Phys. 111, 272-277.
40. Hirunpetcharat, C., Finkelman, F., Clark, I. A. and Good, M. F. (1999). Malaria parasite-specific Th1-like T cells simultaneously reduce parasitemia and promote disease. Parasite Immunol. 21, 319-329.
41. Hisaeda, H., Saul, A., Reece, J. J., Kennedy, M. C., Long, C. A., Miller, L. H. and Stowers, A. W. (2002). Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J. Infect. Dis. 185, 657-664.
42. Hodder, A. N., Crewther, P. E. and Anders, R. F. (2001). Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immunol. 69, 3286-3294.
43. Hoffman, S. L., Oster, C. N., Plowe, C. V., Woollett, G. R., Beier, J. C., Chulay, J. D., Wirtz, R. A., Hollingdale, M. R. and Mugambi, M. (1987). Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 237, 639-642.
44. Holder, A. A. (1996). Preventing merozoite invasion of erythrocytes. In Malaria Vaccine Development: A Multi-Immune Response Approach (ed. S. L. Hoffman), pp. 77-104. Washington, D.C.: American Society for Microbiology.
45. Hui, G. S. and Hashimoto, C. N. (1998). Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1. Infect. Immunol. 66, 5329-5336.
46. Inselburg, J., Bathurst, I. C., Kansopon, J., Barr, P. J. and Rossan, R. (1993). Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant. Infect. Immunol. 61, 2048-2052.
47. Jones, T. R., Narum, D. L., Gozalo, A. S., Aguiar, J., Fuhrmann, S. R., Liang, H., Haynes, J. D., Moch, J. K., Lucas, C., Luu, T. et al. (2001). Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J. Infect. Dis. 183, 303-312.
48. Kedzierski, L., Black, C. G., Goschnick, M. W., Stowers, A. W. and Coppel, R. L. (2002). Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii. Infect. Immunol. 70, 6606-6613.
49. Keitel, W. A., Kester, K. E., Atmar, R. L., White, A. C., Bond, N. H., Holland, C. A., Krzych, U., Palmer, D. R., Egan, A., Diggs, C. et al. (1999). Phase I trial of two recombinant vaccines containing the 19 kD carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 18, 531-539.
50. Kumar, S., Epstein, J. E. and Richie, T. L. (2002). Vaccines against asexual stage malaria parasites. Chem. Immunol. 80, 262-286.
51. Kwiatkowski, D. and Marsh, K. (1997). Development of a malaria vaccine. Lancet 350, 1696-1701.
52. Lee, E. A., Palmer, D. R., Flanagan, K. L., Reece, W. H., Odhiambo, K., Marsh, K., Pinder, M., Gravenor, M. B., Keitel, W. A., Kester, K. E. et al. (2002). Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect. Immunol. 70, 1417-1421.
53. Leech, J. H., Barnwell, J. W., Miller, L. H. and Howard, R. J. (1984). Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-intected erythrocytes. J. Exp. Med. 159, 1567-1575.
54. McGregor, I. A. (1964). The passive transfer of human malarial immunity. Am. J. Trop. Med. Hyg. 13, 237-239.
55. Miller, L. H., Baruch, D. I., Marsh, K. and Doumbo, O. K. (2002). The pathogenic basis of malaria. Nature 415, 673-679.
56. Moorthy, V. and Hill, A. V. (2002). Malaria vaccines. Br. Med. Bull. 62, 59-72.
57. O'Donnell, R. A., Saul, A., Cowman, A. F. and Crabb, B. S. (2000). Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species. Nat. Med. 6, 91-95.
58. Oeuvray, C., Bouharoun-Tayoun, H., Gras-Masse, H., Bottius, E., Kaidoh, T., Aikawa, M., Filgueira, M. C., Tartar, A. and Druilhe, P. (1994a). Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84, 1594-1602.
59. Oeuvray, C., Bouharoun-Tayoun, H., Grass-Masse, H., Lepers, J. P., Ralamboranto, L., Tartar, A. and Druilhe, P. (1994b). A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Mem. Inst. Oswaldo Cruz 89 Suppl. 2, 77-80.
60. Oeuvray, C., Theisen, M., Rogier, C., Trape, J. F., Jepsen, S. and Druilhe, P. (2000). Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect. Immunol. 68, 2617-2620.
61. Patarroyo, M. E., Amador, R., Clavijo, P., Moreno, A., Guzman, F., Romero, P., Tascon, R., Franco, A., Murillo, L. A., Ponton, G. et al., (1988). A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332, 158-161.
62. Patarroyo, M. E., Romero, P., Torres, M. L., Clavijo, P., Moreno, A., Martinez, A., Rodriguez, R., Guzman, F. and Cabezas, E. (1987). Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 328, 629-632.
63. Perlmann, P. and Troye-Blomberg, M. (2002). Malaria and the immune system in humans. Chem. Immunol. 80, 229-242.
64. Pombo, D. J., Lawrence, G., Hirunpetcharat, C., Rzepczyk, C., Bryden, M., Cloonan, N., Anderson, K., Mahakunkijcharoen, Y., Martin, L. B., Wilson, D. et al. (2002). Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360, 610-617.
65. Richie, T. L. and Saul, A. (2002). Progress and challenges for malaria vaccines. Nature 415, 694-701.
66. Ridley, R. G., Takacs, B., Lahm, H. W., Delves, C. J., Goman, M., Certa, U., Matile, H., Woollett, G. R. and Scaife, J. G. (1990). Characterisation and sequence of a protective rhoptry antigen from Plasmodium falciparum. Mol. Biochem. Parasitol. 41, 125-134.
67. Rzepczyk, C. M., Lopez, J. A., Anderson, K. L. and Alpers, M. P. (1988). Investigation of the effect of monocytes with Papua New Guinea sera on Plasmodium falciparum in culture. J. Parasitol. 18, 401-406.
68. Sachs, J. and Malaney, P. (2002). The economic and social burden of malaria. Nature 415, 680-685.
69. Saul, A. (1987). Kinetic constraints on the development of a malaria vaccine. Parasite Immunol. 9, 1-9.
70. Saul, A., Lawrence, G., Smillie, A., Rzepczyk, C. M., Reed, C., Taylor, D., Anderson, K., Stowers, A., Kemp, R., Allworth, A. et al. (1999). Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17, 3145-3159.
71. Schofield, L. (2002). Antidisease vaccines. Chem. Immunol. 80, 322-342.
72. Seixas, E., Fonseca, L. and Langhorne, J. (2002). The influence of gammadelta T cells on the CD4+ T cell and antibody response during a primary Plasmodium chabaudi chabaudi infection in mice. Parasite Immunol. 24, 131-140.
73. Shi, Y. P., Udhayakumar, V., Oloo, A. J., Nahlen, B. L. and Lal, A. A. (1999). Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am. J. Trop. Med. Hyg. 60, 135-141.
74. Sim, B. K., Chitnis, C. E., Wasniowska, K., Hadley, T. J. and Miller, L. H. (1994). Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 264, 1941-1944.
75. Stoute, J. A., Kester, K. E., Krzych, U., Wellde, B. T., Hall, T., White, K., Glenn, G., Ockenhouse, C. F., Garcon, N., Schwenk, R. et al. (1998). Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178, 1139-1144.
76. Stowers, A. and Carter, R. (2001). Current developments in malaria transmission-blocking vaccines. Expert Opin. Biol. Ther. 1, 619-628.
77. Stowers, A. W., Kennedy, M. C., Keegan, B. P., Saul, A., Long, C. A. and Miller, L. H. (2002). Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect. Immunol. 70, 6961-6967.
78. Theisen, M., Dodoo, D., Toure-Balde, A., Soe, S., Corradin, G., Koram, K. K., Kurtzhals, J. A., Hviid, L., Theander, T., Akanmori, B. et al. (2001). Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity. Infect. Immunol. 69, 5223-5229.
79. Troye-Blomberg, M. (2002). Genetic regulation of malaria infection in humans. Chem. Immunol. 80, 243-252.
80. Urban, B. C., Mwangi, T., Ross, A., Kinyanjui, S., Mosobo, M., Kai, O., Lowe, B., Marsh, K. and Roberts, D. J. (2001). Peripheral blood dendritic cells in children with acute Plasmodium falciparum malaria. Blood 98, 2859-2861.
81. von der Honarvar, W. T., Honarvar, N. and Langhorne, J. (1996). Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J. Immunol. 156, 2510-2516.
82. Weidanz, W. P., Brake, D. A., Cavacini, L. A. and Long, C. A. (1988). The protective role of T cells in immunity to malaria. Adv. Exp. Med. Biol. 239, 99-111.
83. Wipasa, J., Elliott, S., Xu, H. and Good, M. F. (2002). Immunity to asexual blood stage malaria and vaccine approaches. Immunol. Cell Biol. 80, 401-414.
84. Xu, H., Wipasa, J., Yan, H., Zeng, M., Makobongo, M. O., Finkelman, F. D., Kelso, A. and Good, M. F. (2002). The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection. J. Exp. Med. 195, 881-892.